---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-021348"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:44:31.380697+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Equillium reports itolizumab Phase 2 UC topline: 23.3% clinical remission vs 10% placebo

## Summary
- Primary endpoint: 23.3% clinical remission at week 12 for itolizumab vs 20.0% adalimumab, 10.0% placebo.
- Secondary: 63.3% clinical response (itolizumab) vs 60.0% adalimumab, 46.7% placebo; endoscopic remission 16.7% each itolizumab/adalimumab vs 6.7% placebo.
- Baseline imbalance: 23% of itolizumab arm had severe disease (Mayo=11) vs 0% placebo/adalimumab; 66% left-sided colitis vs 30%/43%.
- Itolizumab was generally well tolerated with no new safety signal; 90 patients randomized 1:1:1 in India.

## SEC filing metadata
- accession: 0001193125-25-021348
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312525021348/0001193125-25-021348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312525021348/d898732d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-021348
- JSON: https://secwatch.observer/filing/0001193125-25-021348.json
- Plain text: https://secwatch.observer/filing/0001193125-25-021348.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.